Category | Big biotech

When de-risking, relationships matter: How using key strategies can get you to your next innovative partnership

Posted on 10 August 2015

An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration.

Tags: , , , ,

Morphosys acquires Lanthio Pharma

Posted on 07 May 2015

MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.

Tags: ,

Alexion to buy Synageva Biopharma

Posted on 05 May 2015

Alexion Pharmaceuticals have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015.

Tags: ,

Celgene acquires Quanticel Pharmaceuticals

Posted on 28 April 2015

Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel

Tags: , , ,

MedImmune and Immunocore partner for melanoma combinations

Posted on 20 April 2015

Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100

Tags: , ,

Mesoblast banks $45mn financing from Celgene

Posted on 14 April 2015

Mesoblast has entered into an Agreement with Celgene

Tags: , ,

Morphosys regains MOR202 rights from Celgene

Posted on 27 March 2015

MorphoSys has regained rights to MOR202 from Celgene

Tags: , , , ,

Celgene and Open Monoclonal Tech in OmniAb alliance

Posted on 12 March 2015

Open Monoclonal Technology announced license that provides Celgene with unlimited access to OMT’s proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics

Tags: , ,

MedImmune partners with Joslin for diabetes

Posted on 12 March 2015

MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders

Tags: , ,

Alexion and Blueprint partner on activated kinase target

Posted on 04 March 2015

Blueprint Medicines announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates

Tags: , ,